NASDAQ: ENVBEnveric Biosciences Inc Stock
$4.09+0.14 (+3.54%)
Updated Jun 5, 2023
ENVB Price
$4.09
Fair Value Price
$40.83
Market Cap
$8.50M
52 Week Low
$1.30
52 Week High
$18.50
P/E
-0.36x
P/B
0.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.52
Operating Cash Flow
-$18M
Beta
1.24
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENVB Overview
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENVB ($4.09) is undervalued by 89.98% relative to our estimate of its Fair Value price of $40.83 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ENVB ($4.09) is significantly undervalued by 89.98% relative to our estimate of its Fair Value price of $40.83 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ENVB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENVB due diligence checks available for Premium users.
Be the first to know about important ENVB news, forecast changes, insider trades & much more!
ENVB News
Valuation
ENVB fair value
Fair Value of ENVB stock based on Discounted Cash Flow (DCF)
Price
$4.09
Fair Value
$40.83
Undervalued by
89.98%
ENVB ($4.09) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENVB ($4.09) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENVB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENVB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
11.59x
Market
53.21x
ENVB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
5.21x
ENVB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENVB's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.7M
Profit Margin
0%
ENVB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.9M
Liabilities
$5.4M
Debt to equity
0.52
ENVB's short-term assets ($14.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENVB's short-term assets ($14.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENVB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.1M
Investing
-$5.2k
Financing
$0.0
ENVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENVB vs Biotech Stocks
Enveric Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.